Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have earned an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.50.
MRSN has been the subject of a number of research reports. Zacks Investment Research raised shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Mersana Therapeutics in a report on Thursday, November 7th. Finally, ValuEngine raised shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. NEA Management Company LLC grew its holdings in Mersana Therapeutics by 0.6% during the 3rd quarter. NEA Management Company LLC now owns 11,963,649 shares of the company’s stock worth $18,903,000 after acquiring an additional 69,382 shares during the period. Walleye Trading Advisors LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $57,000. Walleye Trading LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $54,000. Susquehanna International Group LLP acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $154,000. Finally, Boxer Capital LLC acquired a new stake in Mersana Therapeutics during the 2nd quarter worth $8,440,000. 83.50% of the stock is owned by hedge funds and other institutional investors.
Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. As a group, analysts anticipate that Mersana Therapeutics will post -0.6 EPS for the current year.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
See Also: Is the QQQ ETF safe?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.